Generalized Intense Pruritus During Canagliflozin Treatment : Is it an Adverse Drug Reaction?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
BACKGROUND: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion.
CASE DESCRIPTION: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus.
CONCLUSION: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Current drug safety - 13(2018), 1 vom: 05., Seite 38-40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vasapollo, Piero [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0SAC974Z85 |
|---|
| Anmerkungen: |
Date Completed 20.09.2018 Date Revised 20.09.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574886311666160405110515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM259110507 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM259110507 | ||
| 003 | DE-627 | ||
| 005 | 20231224190457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886311666160405110515 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0863.xml |
| 035 | |a (DE-627)NLM259110507 | ||
| 035 | |a (NLM)27048192 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vasapollo, Piero |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generalized Intense Pruritus During Canagliflozin Treatment |b Is it an Adverse Drug Reaction? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2018 | ||
| 500 | |a Date Revised 20.09.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a BACKGROUND: Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion | ||
| 520 | |a CASE DESCRIPTION: We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus | ||
| 520 | |a CONCLUSION: This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pruritus | |
| 650 | 4 | |a SGLT2 | |
| 650 | 4 | |a adverse drug reaction | |
| 650 | 4 | |a canagliflozin | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a sodium-glucose. | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Canagliflozin |2 NLM | |
| 650 | 7 | |a 0SAC974Z85 |2 NLM | |
| 700 | 1 | |a Cione, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Luciani, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 13(2018), 1 vom: 05., Seite 38-40 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:1 |g day:05 |g pages:38-40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886311666160405110515 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 1 |b 05 |h 38-40 | ||